Drs Kathy D. Miller and Heather A. Parsons explore the complexities and evolving strategies in managing HER2+ oligometastatic ...

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...

The high prevalence of depression and anxiety among patients with MBC correlates with diminished survival rates and ...

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of ...

FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel ...

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...

PFS came in at 61.6% overall, at 62.9% in those with stable brain metastases, and at 59.6% in those with active brain ...

The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...

1 Ribociclib is manufactured by Novartis for early breast cancer and advanced or metastatic breast cancer. 2 The approval was supported by the NATALEE (NCT03701334) trial, a randomized, open-label, ...